BIMINI Biotech’s MIT Feasibility grant AUTO-WASP awarded

BIMINI Biotech has received a MIT feasibility grant (€20.000) for the AUTO-WASP project. The Mkb-innovatiestimulering Regio en Topsectoren (MIT) stimulates innovation in small and medium-sized enterprises across regional borders. In addition, MIT encourages SME projects to better align with the knowledge and innovation agendas of the Missions for the future. This enables companies to carry out a feasibility project to map the technical and economic risks of a proposed innovation project.

BIMINI’s uniquely targets the Wiskott-Aldrich Syndrome protein (WASP) that has shown strong in vivo potential in several tumor types. Beyond oncology, WASP also plays critical roles in innate and adaptive immunity including immune synapse formation, cell signaling, migration and cytokine release. Dysregulation of WASP function has been shown to result in auto-immune disorders such as colitis and arthritis. Increasing WASP function such as by increasing expression levels in these mice models can ameliorate the disease symptoms including immune dysregulation. Based on these scientific results, we have identified a therapeutic portfolio extension possibility for our WASP modulation approach in autoimmune disorders. The AUTO-WASP project aims to investigate the technical and economic feasibility of applying the technology in two autoimmune disorders

The AUTO-WASP project is supported by the Province of Zuid-Holland,